Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver

NCT00035919 | Withdrawn Phase 1

• 1 other identifier: 3C-01-2
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a Phase I safety study of a gene transfer drug for colorectal cancer that has spread to the liver. The main purpose of this study is to determine if it is safe to give this new intervention to persons with cancer, but we will also look for indications that the drug is effective. Although the findings in animals that have cancer are encouraging, this is the first time humans will receive this experimental gene transfer drug. A gene called cyclin G1 has been shown to play a very important part in cancer growth. In animal experiments, a genetically modified virus (or vector)carrying a modified cyclin G1 gene caused the cancerous tumors to grow much slower or even die. In this safety study, the drug will be injected through the liver artery to get it near the cancer that has spread to the liver. The way the gene gets into the cancer cells is by using a targeted vector that concentrates in the area of the cancer to improve the delivery of the killing gene into cancer cells. The vector we are using is a virus that has been changed so that the infectious genes have been removed and instead carries the modified cyclin G1 gene.

Conditions

Colorectal Neoplasms

Keywords

Colon cancer; Targeted Injectable Vector; Gene Transfer; Gene Therapy; Retroviral vector

Outcome Measures

Primary Outcomes (1)

• dose-limiting toxicity and maximum tolerated dose

Secondary Outcomes (1)

• objective tumor response by CT scan or MRI

Interventions

Mx-dnG1 Retroviral Vector GENETIC

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically or cytologically confirmed colorectal carcinoma metastatic to liver, which is unresectable based on the judgment of the patient's surgeon) and is radiologically measurable.
• Adequate hepatic function: Total bilirubin \< 2.0 mg/dL (upper limit included); AST/ALT \< 2x institutional norm; alkaline phosphatase \< 3x upper limit of institutional norm, albumin \> 3.0 mg/dL. There must be no substantial ascites. PT and PTT must be within normal limits.
• Performance status must be 0-1 (SWOG 0-1) with a life expectancy of at least 3 months.
• Absolute granulocyte count \> 1000/uL, and platelet count \> 100,000/uL.
• Calculated creatinine clearance \> 60ml/hour.
• There must be no plans for the patient to receive further cancer therapy from the date of enrollment until the completion of the 12 week follow-up visit.
• Installation of a functional hepatic arterial infusion (HAI) with satisfactory positioning of the catheter in a primary branch of the hepatic artery, placed within the prior 6 months to three weeks. If the patient does not presently have a hepatic artery infusion pump in place, a pump can be placed for them so that they might qualify to participate in the intervention and follow-up phases of this clinical trial.
• Age \> 18 years, in order to protect children or minors from the potential risks of a new drug that has not yet been tested in adults.
• The ability to understand and the willingness to sign a written informed -consent document.

You may not qualify if:

• Prior malignancy, except for non-melanoma skin cancer, stage I breast cancer, CIS of cervix from which the patient has been disease free for 5 years.
• Woman who are pregnant or nursing
• Fertile patients unless they agree to use barrier contraception (condoms and spermicide jelly) during the vector infusion period and for six weeks after infusion.
• Patients with medical, psychiatric, or social conditions that would compromise successful adherence to this protocol.
• Patients with indwelling biliary stents or a recent history of cholangitis, hepatitis, presence of disseminated intravascular coagulopathy, or HIV infection. Patients must not have a history of recent myocardial infarction (within one year) or evidence of congestive heart failure.
• Patients with a history of bleeding varices in the prior 3 months.
• Patients who have received any other antitumor treatment (chemotherapy, radiation, immunotherapy) within 4 weeks of study entry or who have not recovered from previous therapy or within 6 weeks for mitomycin C and nitrosureas.

Sponsors & Collaborators

• University of Southern California: lead

MeSH Terms

Conditions

Colorectal Neoplasms; Colonic Neoplasms

Interventions

retrovector encoding mutant anti-cyclin G1

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: May 6, 2002
• First Posted: May 7, 2002
• Study Start: November 1, 2002
• Study Completion: October 1, 2003
• Last Updated: May 22, 2014

Record last verified: 2014-05